Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05623878
68Ga-labeled NY108 PET Imaging in Patients
Overview
This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled NY108 (89Zr-NY108) PET Imaging in patients with Prostate cancer.
Phase
Early Phase 1
ClinicalTrials.gov
NCT05623878Drug / Compound
Isotope(s):
ZIRCONIUM-89
Radioisotope: Zr89
Theranostic Role: PET Imaging
T1/2 (Half-Life): 78 Hours
Decay Mode: POSITRON β+ (22%), ELECTRON CAPTURE (76%), GAMMA
Energy: max 0.9 MeV, E mean 397 keV, Gamma 511 keV
Range: N/A
Decay Daughters: Y89 (Stable)
Status: Clinical Trials Only
Target(s):
Share your feedback
Help us improve your experience